By Chris Wack

Alpine Immune Sciences Inc. said it is in a clinical trial collaboration and supply agreement with Merck.

The company said the collaboration will evaluate the safety and efficacy of Alpine's ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck's anti-PD-1 therapy Keytruda pembrolizumab.

The clinical trial began dosing study participants in June.

Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.

Alpine shares were up 9%, to $9.89, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 30, 2021 08:30 ET (12:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.